JP7224331B2 - 脂肪毒性損傷の低減のための化合物 - Google Patents
脂肪毒性損傷の低減のための化合物 Download PDFInfo
- Publication number
- JP7224331B2 JP7224331B2 JP2020501125A JP2020501125A JP7224331B2 JP 7224331 B2 JP7224331 B2 JP 7224331B2 JP 2020501125 A JP2020501125 A JP 2020501125A JP 2020501125 A JP2020501125 A JP 2020501125A JP 7224331 B2 JP7224331 B2 JP 7224331B2
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- pharmaceutical composition
- compound
- subject
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D305/10—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having one or more double bonds between ring members or between ring members and non-ring members
- C07D305/12—Beta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Epoxy Compounds (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762531454P | 2017-07-12 | 2017-07-12 | |
| US62/531,454 | 2017-07-12 | ||
| PCT/US2018/041796 WO2019014434A1 (en) | 2017-07-12 | 2018-07-12 | COMPOUNDS FOR REDUCING LIPOTOXIC LESIONS |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020527138A JP2020527138A (ja) | 2020-09-03 |
| JP2020527138A5 JP2020527138A5 (https=) | 2021-08-12 |
| JP7224331B2 true JP7224331B2 (ja) | 2023-02-17 |
Family
ID=65002124
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020501125A Active JP7224331B2 (ja) | 2017-07-12 | 2018-07-12 | 脂肪毒性損傷の低減のための化合物 |
Country Status (14)
| Country | Link |
|---|---|
| US (5) | US11339126B2 (https=) |
| EP (2) | EP3651784B1 (https=) |
| JP (1) | JP7224331B2 (https=) |
| KR (1) | KR102679975B1 (https=) |
| CN (1) | CN111343999B (https=) |
| AU (2) | AU2018300985B2 (https=) |
| BR (1) | BR112020000635B1 (https=) |
| CA (1) | CA3069526A1 (https=) |
| DK (1) | DK4218753T3 (https=) |
| ES (1) | ES2934883T3 (https=) |
| IL (1) | IL271884B2 (https=) |
| PL (2) | PL4218753T3 (https=) |
| SG (1) | SG11202000239XA (https=) |
| WO (1) | WO2019014434A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202000239XA (en) | 2017-07-12 | 2020-02-27 | Mayo Found Medical Education & Res | Compounds for the reducing lipotoxic damage |
| MX2023012532A (es) * | 2021-04-23 | 2023-11-29 | Panafina Inc | Metodos de sintetizacion de derivados de lipstatina. |
| CN114560887B (zh) * | 2022-02-15 | 2024-01-26 | 安徽美致诚药业有限公司 | 一种制备奥利司他的中间体的制备方法 |
| AU2023243617A1 (en) * | 2022-03-31 | 2024-10-03 | Mayo Foundation For Medical Education And Research | Methods and materials for treating pancreatic diseases and disorders |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007523131A (ja) | 2004-02-23 | 2007-08-16 | ゾルファイ ファーマスーティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング | リパーゼ抑制剤としてのアルキルカルバマート置換したβ−ラクトン |
| US20120289588A1 (en) | 2011-04-15 | 2012-11-15 | Vijay Prem Singh | Lipase Inhibitors for the Treatment of Pancreatitis and Organ Failure |
| US20150099800A1 (en) | 2012-05-24 | 2015-04-09 | Northeastern University | Novel lipase inhibitors, reporter substrates and uses thereof |
| WO2016102541A1 (en) | 2014-12-22 | 2016-06-30 | Université Libre de Bruxelles | Composition comprising vancomycin and orlistat |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA859575B (en) * | 1984-12-21 | 1986-08-27 | Hoffmann La Roche | Oxetanones |
| CA1270837A (en) * | 1984-12-21 | 1990-06-26 | Hoffmann-La Roche Limited | Oxetanones |
| IL97148A (en) * | 1990-02-26 | 1996-11-14 | Hoffmann La Roche | Oxetanones a process for their manufacture and pharmaceutical compositions containing them |
| FR2754827B1 (fr) | 1996-10-17 | 1998-12-24 | Biocem | Lipases pancreatiques et/ou colipases recombinantes et polypeptides dervies produits par les plantes, leurs procedes d'obtention et leurs utilisations |
| FR2758143B1 (fr) | 1997-01-07 | 1999-02-19 | Laphal Laboratoire De Pharmaco | Inhibiteurs specifiques de la lipase pancreatique et leurs applications |
| US7060708B2 (en) | 1999-03-10 | 2006-06-13 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
| US8980290B2 (en) | 2000-08-03 | 2015-03-17 | Antares Pharma Ipl Ag | Transdermal compositions for anticholinergic agents |
| US20040018197A1 (en) | 2002-04-26 | 2004-01-29 | Promega Corporation | Treatment for weight loss |
| EP1803714A1 (en) | 2005-12-27 | 2007-07-04 | KRKA, tovarna zdravil, d.d., Novo mesto | Process for preparing crystalline forms of orlistat |
| WO2009059046A1 (en) | 2007-10-31 | 2009-05-07 | Burnham Institute For Medical Research | Beta-lactone compounds |
| CN106470804B (zh) | 2014-06-30 | 2019-09-10 | 工机控股株式会社 | 电动工具 |
| US20180319894A1 (en) | 2015-11-03 | 2018-11-08 | Mayo Foundation For Medical Education And Research | Using colipase inhibitors to treat pancreatitis |
| SG11202000239XA (en) | 2017-07-12 | 2020-02-27 | Mayo Found Medical Education & Res | Compounds for the reducing lipotoxic damage |
-
2018
- 2018-07-12 SG SG11202000239XA patent/SG11202000239XA/en unknown
- 2018-07-12 EP EP18831486.8A patent/EP3651784B1/en active Active
- 2018-07-12 PL PL22197886.9T patent/PL4218753T3/pl unknown
- 2018-07-12 JP JP2020501125A patent/JP7224331B2/ja active Active
- 2018-07-12 PL PL18831486.8T patent/PL3651784T3/pl unknown
- 2018-07-12 EP EP22197886.9A patent/EP4218753B1/en active Active
- 2018-07-12 KR KR1020207003413A patent/KR102679975B1/ko active Active
- 2018-07-12 AU AU2018300985A patent/AU2018300985B2/en active Active
- 2018-07-12 ES ES18831486T patent/ES2934883T3/es active Active
- 2018-07-12 WO PCT/US2018/041796 patent/WO2019014434A1/en not_active Ceased
- 2018-07-12 CN CN201880057761.7A patent/CN111343999B/zh active Active
- 2018-07-12 US US16/629,842 patent/US11339126B2/en active Active
- 2018-07-12 DK DK22197886.9T patent/DK4218753T3/da active
- 2018-07-12 CA CA3069526A patent/CA3069526A1/en active Pending
- 2018-07-12 BR BR112020000635-1A patent/BR112020000635B1/pt active IP Right Grant
-
2020
- 2020-01-07 IL IL271884A patent/IL271884B2/en unknown
-
2022
- 2022-04-20 US US17/725,281 patent/US11623915B2/en active Active
-
2023
- 2023-03-03 US US18/178,062 patent/US11976040B2/en active Active
-
2024
- 2024-04-17 US US18/637,793 patent/US12325690B2/en active Active
- 2024-12-11 AU AU2024278291A patent/AU2024278291A1/en active Pending
-
2025
- 2025-05-14 US US19/207,836 patent/US20250340512A1/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007523131A (ja) | 2004-02-23 | 2007-08-16 | ゾルファイ ファーマスーティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング | リパーゼ抑制剤としてのアルキルカルバマート置換したβ−ラクトン |
| US20120289588A1 (en) | 2011-04-15 | 2012-11-15 | Vijay Prem Singh | Lipase Inhibitors for the Treatment of Pancreatitis and Organ Failure |
| US20150099800A1 (en) | 2012-05-24 | 2015-04-09 | Northeastern University | Novel lipase inhibitors, reporter substrates and uses thereof |
| WO2016102541A1 (en) | 2014-12-22 | 2016-06-30 | Université Libre de Bruxelles | Composition comprising vancomycin and orlistat |
Non-Patent Citations (2)
| Title |
|---|
| Journal of Medicinal Chemistry，2008年，51(21)，P.6970-6979 |
| Journal of the Chemical Society, Perkin Transactions 1，1998年，(8)，P.1373-1382 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12325690B2 (en) | Compounds for the reducing lipotoxic damage | |
| US8569536B2 (en) | C-nitroso-derived nitroxyl donors | |
| US11319292B2 (en) | Metabolically stable 5-HMF derivatives for the treatment of hypoxia | |
| US20220184032A1 (en) | Indoline derivatives for treatment and/or prevention of fibrosis diseases | |
| RU2776343C2 (ru) | Соединения для снижения липотоксического повреждения | |
| JP2014510138A (ja) | 治療計画 | |
| HK40029799A (en) | Compounds for the reducing lipotoxic damage | |
| HK40029799B (en) | Compounds for the reducing lipotoxic damage | |
| JPWO1996006825A1 (ja) | グアニジノメチルシクロヘキサンカルボン酸エステル誘導体 | |
| US12583834B2 (en) | Method of treating bacterial infections and pharmaceutical composition for treating bacterial infections | |
| US20060167269A1 (en) | Compounds and methods for the inhibition of compounds cruzi |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210630 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210630 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20220616 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220628 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220922 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230110 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230207 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7224331 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |